Single gene or panel testing – how can we balance clinical value and timely reporting?
In this presentation aimed at Cancer MDTs, Dr Mike Hubank and Dr Gareth Gerrard provide an overview of the cancer diagnostic tests available in England and the evolving role of panel testing and single/low number gene testing.
Dr Mike Hubank is Scientific Director North Thames GLH, and Dr Gareth Gerrard is Lead Scientist for Cancer Genomics South East GLH.
This was recorded in September 2022 as part of the Bayer sponsored educational event Everything you want to know about genomics but are afraid to ask, which explored the benefits and challenges of mainstreaming genomic profiling and precision oncology pathways in the management of patients with cancer.
You can view the other presentations from the meeting by following the links below;
- Why should we genomically profile our patients? A clinician’s perspective. Dr Nirupa Murugaesu, Consultant Medical Oncologist at St George’s University Hospitals NHS Foundation Trust, Cancer Lead for Genomics, South East GLH.
- How can we optimise tissue samples for genomic testing and minimise failures? Professor Louise Jones, Pathology Lead, North Thames GLH
- Single gene or panel testing – how can we balance clinical value and timely reporting? Dr Mike Hubank, Scientific Director North Thames GLH, and Dr Gareth Gerrard, Lead Scientist for Cancer Genomics South East GLH.
- From bench to bedside – how can we maximise the value of genomic reports? Dr Nirupa Murugaesu, Consultant Medical Oncologist at St George’s University Hospitals NHS Foundation Trust, Cancer Lead for Genomics, South East GLH.
- What has genomic testing ever done for us? Patient Case Studies. Dr Riyaz Shah, Consultant Medical Oncologist, Maidstone and Tunbridge Wells NHS Trust, Kent. This presentation was sponsored by Bayer and discussed Bayer products, and therefore the video is hosted on a Bayer promotional website. To leave the North Thames GLH website and access this presentation on the Bayer website, please click here.